Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a syndrome of uncontrolled lymphoid growth in the immunosuppressed transplant patient. Known risk factors include Epstein-Barr virus (EBV) seronegativity at the time of transplant, pediatric age and allograft type. Newer studies suggest that constitutional factors such as cytokine gene polymorphisms may also predispose to PTLD. Although PTLD may occur at any time, the majority of cases arise within the first two post-transplant years. Clinical presentation is heterogeneous and dependent upon the location and extent of disease. Allograft involvement is common, particularly in cases of lung, intestine, or pancreas transplantation. Most PTLD are of B lymphocyte origin. A histopathologic classification system has been proposed and it is important to understand the histology of these lesions, since the term PTLD incorporates both hyperplastic and neoplastic growths. Histologic subclassification also has prognostic value, although this remains imperfect at present. Clinical evaluation should include staging as for lymphomas, since PTLD stage is an important determinant of outcome. In EBV-associated PTLD, quantitative evaluation of EB viral genomic load has a role in guiding prophylaxis, diagnosis, and monitoring of therapy. The presence of EBV is not an absolute requirement for the diagnosis of PTLD, and it has been suggested that there has been a recent increase in the number of EBV-negative cases. Such lesions have a median onset time around 50–60 months post-transplant. Therapy of PTLD must be tailored to the individual patient. Newer modalities such as anti-CD20 antibodies are being evaluated and may complement the standard stepwise approach that begins with a reduction of immunosuppression. The role of chemotherapy continues to be defined, and in some cases early recourse to this approach may be desirable. Survival varies by age and extent of disease, with pediatric patients and those with localized disease tending to fare better. A finer understanding of the molecular cellular and virologie underpinnings of PTLD remains essential in order to define optimal treatment regimens. The emergence of EBV-negative PTLD is a problem and the relationship of this to standard lymphomas arising in nonimmunosuppressed patients remains to be defined. Continued individual and multi-institutional studies are essential for progress in these areas.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Starzl TE (1968) Discussion of Murray JE, Wilson RE, Tilney NL et al. Five years’ experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg 168:416
Shapiro R, Nalesnik M, McCauley J, Fedorek S, Jordan ML, Scantlebury VP, Jain A, Vivas C, Ellis D, Lombardozzi-Lane S, Randhawa P, lohnston J, Hakala TR, Simmons RL, Fung JJ, Starzl TE (1999) Posttrans plant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimusbased immunosuppression. Transplantation 68:1851–1854
Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, Atchison RW, Karrer F, Nalesnik MA, Starzl TE (1988) The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:719–727
Manez R, Breinig MC, Linden P, Wilson J, Torre-Cisneros J, Kusne S, Dummer S, Ho M (1997) Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 176:1462–1467
Swinnen LJ, Costanzo-Nordin MK, Fisher SG, O’Sullivan EJ, lohnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 323:1723–1728
Bhatia S, Ramsay NKC, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ, Robison DJ, Miller IS, Neglia JP (1996) Malignant neoplasms following bone marrow transplantation. Blood 87:3633–3639
Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Jr, Whitington PF (1997) Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr 131:98–104
Hezode C, Duvoux C, Germanidis G, Roudot-Thoraval F, Vincens AL, Gaulard P, Cherqui D, Pawlotsky JM, Dhumeaux D (1999) Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology 30:775–778
McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, levnikar AM, Rizkalla KS (2000) Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transplant 6:570–574
Shpilberg O, Wilson J, Whiteside TL, Herberman RB (1999) Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 36:109–121
Cohen AH, Sweet SC, Mendeloff E, Mallory GB Jr., Huddleston CB, Kraus M, Kelly M, Hayashi R, DeBaun MR (2000) High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med 161:1252–1255
Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot E, Hardt C, D’Alfonso S (1999) Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1:3–19
Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK (1999) Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67:876–881
Nalesnik MA, Zeevi A, Randhawa PS, Faro A, Spichty KJ, Demetris AJ, Fung JJ, Whiteside TL, Starzl TE (1999) Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin Transplant 13:39–44
Malatack JJ, Gartner JC, Urbach AH, Zitelli BJ (1991) Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: a growing concern. J Pediatr 118:667–675
Penn I (1994) The problem of cancer in organ transplant recipients: an overview. Transplant Sci 4:23–32
Chen JM, Barr ML, Chadburn A, Frizzera G, Schenkel FA, Sciacca RR, Reison DS, Addonizio LJ, Rose EA, Knowles DM, et al (1993) Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 56:527–538
Martinez AJ, Ahdab-Barmada M (1993) The neuropathology of liver transplantation: comparison of main complications in children and adults. Mod Pathol 6:25–32
Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, Holahan KP, Lindquist LL (1981) Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 41:4262–4279
Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173–192
Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE (1995) Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565
Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14:8–14
Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS (1999) Epstein-Barr virusinduced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517–1525
Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, Knowles DM (1998) BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 92:2294–2302
Locker J, Nalesnik M (1989) Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 135:977–987
Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE (1995) Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 89:98–103
Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, Todo S, Green M (1997) Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 35:1612–1615
Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J. (2000) Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 70:593–596
Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D (2000) Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 182:1013–1021
Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH (2000) Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 24:375–385
Leblond V, Davi F, Charlotte F Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M (1998) Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 16:2052–2059
Drexler HG, Uphoff CC, Gaidano G, Carbone A (1998) Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas). Leukemia 12:1507–1517
Rickinson AB, Kieff E (1996) Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Fields virology, vol 3. Philadelphia: Lippincott-Raven, pp 2397–2446
Swinnen LJ (2000) Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 11 [Suppll]:45–48
Benkerrou M, Durandy A, Fischer A (1993) Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 7:467–475
Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief E Mathieu-Boue A, Leblond V (2000) Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 11:113–116.
Cohen JI (1991) Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 70:137–160
Hsi ED, Singleton TP, Swinnen L, Dunphy CH, Alkan S (2000) Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 24:100–106
Dockrell DH, Strickler IG, Paya CV (1998) Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients. Clin Infect Dis 26:180–182
Lones MA, Lopez-Terrada D, Weiss LM, Shintaku IP, Said fW (1997) Donor origin of posttransplant lymphoproliferative disorder localized to a liver allograft: demonstration by fluorescence in situ hybridization [see comments]. Arch Pathol Lab Med 121:701–706
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Nalesnik, M.A. (2002). Clinicopathologic Characteristics of Post-Transplant Lymphoproliferative Disorders. In: Oertel, S.H., Riess, H. (eds) Immunosurveillance, Immunodeficiencies and Lymphoproliferations. Recent Results in Cancer Research, vol 159. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56352-2_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-56352-2_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62676-0
Online ISBN: 978-3-642-56352-2
eBook Packages: Springer Book Archive